\BOOKMARK [1][-]{section*.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section*.2}{Results}{}% 2
\BOOKMARK [2][-]{subsection*.3}{Identification of the in vivo WASH complex proteome}{section*.2}% 3
\BOOKMARK [2][-]{subsection*.4}{The SWIPP1019R mutation destabilizes the WASH complex}{section*.2}% 4
\BOOKMARK [2][-]{subsection*.5}{Spatial proteomics analysis of SWIPP1019R mutant mouse brain}{section*.2}% 5
\BOOKMARK [2][-]{subsection*.6}{SWIP mutant neurons display endo-lysosomal structural abnormalities}{section*.2}% 6
\BOOKMARK [2][-]{subsection*.7}{SWIPP1019R mutant brains exhibit lipofuscin accumulation and markers of cell death}{section*.2}% 7
\BOOKMARK [2][-]{subsection*.8}{SWIPP1019R mutant mice display persistent deficits in cued fear memory recall}{section*.2}% 8
\BOOKMARK [2][-]{subsection*.9}{SWIPP1019R mutant mice exhibit surprising motor deficits that are confirmed in human patients}{section*.2}% 9
\BOOKMARK [1][-]{section*.25}{Discussion}{}% 10
\BOOKMARK [1][-]{section*.26}{Acknowledgements}{}% 11
\BOOKMARK [1][-]{section*.27}{Author Contributions}{}% 12
\BOOKMARK [1][-]{section*.28}{Competing Interests}{}% 13
\BOOKMARK [1][-]{section*.29}{Resource Availability}{}% 14
\BOOKMARK [2][-]{subsection*.30}{Lead Contact}{section*.29}% 15
\BOOKMARK [2][-]{subsection*.31}{Materials Availability}{section*.29}% 16
\BOOKMARK [2][-]{subsection*.32}{Data and Code Availability}{section*.29}% 17
\BOOKMARK [1][-]{section*.33}{Materials and Methods}{}% 18
\BOOKMARK [2][-]{subsection*.34}{Animals}{section*.33}% 19
\BOOKMARK [2][-]{subsection*.35}{Human Subjects}{section*.33}% 20
\BOOKMARK [2][-]{subsection*.36}{Cell Lines}{section*.33}% 21
\BOOKMARK [2][-]{subsection*.37}{Primary Neuronal Culture}{section*.33}% 22
\BOOKMARK [2][-]{subsection*.38}{Plasmid DNA Constructs}{section*.33}% 23
\BOOKMARK [2][-]{subsection*.39}{AAV Viral Preparation}{section*.33}% 24
\BOOKMARK [2][-]{subsection*.40}{Immunocytochemistry}{section*.33}% 25
\BOOKMARK [3][-]{subsubsection*.41}{Primary antibodies}{subsection*.40}% 26
\BOOKMARK [3][-]{subsubsection*.42}{Secondary antibodies}{subsection*.40}% 27
\BOOKMARK [2][-]{subsection*.43}{Immunohistochemistry}{section*.33}% 28
\BOOKMARK [3][-]{subsubsection*.44}{Primary antibodies}{subsection*.43}% 29
\BOOKMARK [3][-]{subsubsection*.45}{Secondary antibodies}{subsection*.43}% 30
\BOOKMARK [2][-]{subsection*.46}{Western Blotting}{section*.33}% 31
\BOOKMARK [3][-]{subsubsection*.47}{Primary antibodies}{subsection*.46}% 32
\BOOKMARK [3][-]{subsubsection*.48}{Secondary antibodies}{subsection*.46}% 33
\BOOKMARK [2][-]{subsection*.49}{Immunoprecipitation}{section*.33}% 34
\BOOKMARK [2][-]{subsection*.50}{Electron Microscopy}{section*.33}% 35
\BOOKMARK [2][-]{subsection*.51}{iBioID Sample Preparation}{section*.33}% 36
\BOOKMARK [2][-]{subsection*.52}{LC-MS/MS for iBioID}{section*.33}% 37
\BOOKMARK [2][-]{subsection*.53}{LOPIT-DC Subcellular Fractionation}{section*.33}% 38
\BOOKMARK [2][-]{subsection*.54}{16-plex TMT LC-MS/MS}{section*.33}% 39
\BOOKMARK [2][-]{subsection*.55}{Mouse Behavioral Assays}{section*.33}% 40
\BOOKMARK [3][-]{subsubsection*.56}{Y-maze}{subsection*.55}% 41
\BOOKMARK [3][-]{subsubsection*.57}{Novel Object Recognition}{subsection*.55}% 42
\BOOKMARK [3][-]{subsubsection*.58}{TreadScan}{subsection*.55}% 43
\BOOKMARK [3][-]{subsubsection*.59}{Fear Conditioning}{subsection*.55}% 44
\BOOKMARK [3][-]{subsubsection*.60}{Hearing Test}{subsection*.55}% 45
\BOOKMARK [3][-]{subsubsection*.61}{Somatosensation}{subsection*.55}% 46
\BOOKMARK [1][-]{section*.62}{Quantification and statisical analysis}{}% 47
\BOOKMARK [2][-]{subsection*.63}{Imaris 3D reconstruction}{section*.62}% 48
\BOOKMARK [2][-]{subsection*.64}{Cleaved Caspase-3 Image Analysis}{section*.62}% 49
\BOOKMARK [2][-]{subsection*.65}{iBioID Quantitative Analysis}{section*.62}% 50
\BOOKMARK [2][-]{subsection*.66}{TMT Proteomics Quantitative Analysis}{section*.62}% 51
\BOOKMARK [2][-]{subsection*.67}{Module Gene Set Enrichment Analysis}{section*.62}% 52
\BOOKMARK [2][-]{subsection*.68}{Network Visualization}{section*.62}% 53
\BOOKMARK [1][-]{section*.69}{References}{}% 54
\BOOKMARK [1][-]{section*.70}{Funding Sources}{}% 55
